Report cover image

Global Seasonal Affective Disorder Therapeutics Market Growth, Size, Trends Analysis - By Treatment Type, By Disorder Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Oct 13, 2025
Length 259 Pages
SKU # SPER20565942

Description

Global Seasonal Affective Disorder Therapeutics Market Introduction and Overview

According to SPER market research, ‘Global Seasonal Affective Disorder Therapeutics Market Size- By Treatment Type, By Diagnosis Type, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ states that the Global Seasonal Affective Disorder Therapeutics Market is predicted to reach 1338.53 million by 2034 with a CAGR of 4.98%.

Seasonal Affective Disorder (SAD) is a type of depression that occurs during specific seasons, most notably fall and winter, when natural sunlight is reduced. Light treatment, antidepressant medicines, psychotherapy, and lifestyle changes are all used to treat SAD and improve mood and energy levels. The healthcare and mental health industries are increasingly focusing on creative and patient-friendly techniques to improve treatment accessibility and effectiveness.

Restraints:

Despite rising demand, various barriers prevent the widespread use of Seasonal Affective Disorder treatments. Side effects and black-box warnings on antidepressants frequently reduce patient adherence, lowering long-term effectiveness. Low awareness and underdiagnosis in low- and middle-income countries impede prompt treatment access. Furthermore, payor restrictions for off-label psychedelic or ketamine-based clinics limit the expansion of alternate therapy pathways. Another issue comes with LED light boxes, where rare-earth element supply issues jeopardize production stability and availability.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered By

Treatment Type, By Disorder Type, By End User

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

AbbVie, Amen Clinics, Bausch Health Companies, Cleveland Clinic, Eli Lilly and Company, GlaxoSmithKline, Henry Schein, Johnson & Johnson (Janssen Pharmaceuticals), Mayo Clinic, Novartis.

Global Seasonal Affective Disorder Therapeutics Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Medications, Therapy.

By Disorder Type: Based on the Disorder Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Fall & winter SAD, Spring & summer SAD.

By End User: Based on the End User, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Hospitals, Specialty clinics, Homecare setting, Other end user.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

259 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Seasonal Affective Disorder Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Seasonal Affective Disorder Therapeutics Market
7. Global Seasonal Affective Disorder Therapeutics Market, By Treatment Type (USD Million) 2021-2034
7.1. Medication
7.1.1. Selective serotonin reuptake inhibitors (SSRI)
7.1.2. Norepinephrine-dopamine reuptake inhibitor (NDRI)
7.1.3. Monoamine oxidase inhibitor (MAOI)
7.1.4. Other drug types
7.2. Therapy
7.2.1. Light therapy
7.2.2. Psychotherapy
8. Global Seasonal Affective Disorder Therapeutics Market, By Disorder Type (USD Million) 2021-2034
8.1. Fall & winter SAD
8.2. Spring & summer SAD
9. Global Seasonal Affective Disorder Therapeutics Market, By End User (USD Million) 2021-2034
9.1. Hospitals
9.2. Specialty clinics
9.3. Homecare setting
9.4. Other end use
10. Global Seasonal Affective Disorder Therapeutics Market, (USD Million) 2021-2034
10.1. Global Seasonal Affective Disorder Therapeutics Market Size and Market Share
11. Global Seasonal Affective Disorder Therapeutics Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. AbbVie
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Amen Clinics
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Bausch Health Companies
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Cleveland Clinic
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Eli Lilly and Company
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. GlaxoSmithKlinz
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Henry Schein
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Johnson & Johnson (Janssen Pharmaceuticals)
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Mayo Clinic
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Novartis
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us